| Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment to enable T cells to eliminate tumors. We show 33 historical shares outstanding datapoints in our ADXS shares outstanding history coverage, used to compute ADXS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADXS market cap history over the course of time is important for investors
interested in comparing ADXS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADXS versus a peer is one thing; comparing
ADXS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADXS can fluctuate over the course of history.
With this page we aim to empower investors researching ADXS by allowing them to research the ADXS market cap history.